Featured News

The PROACTIVE Celiac Study is a phase 2 clinical trial testing the safety and effects of the investigational medication PRV-015.

A recent study identified several biochemical abnormalities associated with testing positive for celiac disease in an antibody test. These biochemical abnormalities could be a predictor of celiac disease and become a tool to reduce delayed diagnosis.

A recent study found that avoidant/restrictive food intake disorder (ARFID) is common among people with celiac disease.

The Celiac Disease Foundation is matching donations, dollar for dollar, up to $25,000. Together we can protect those with celiac disease in crisis. 

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

CDF Proud Sponsor Nestlé offers more than 25 gluten-free options to ensure consumers have delicious choices regardless of their dietary needs.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

The Celiac Disease Foundation’s article, “New Legislation Aims to Extend Nutrition Care to Chronic Conditions” was featured in Future of Personal Health.

Researchers from Takeda Pharmaceuticals and the Celiac Disease Foundation presented a study which concluded that despite gluten-free diet adherence, many patients with celiac disease still have symptoms that substantially impact their lives.

The Celiac Disease Foundation is proud to partner with Mediaplanet for their Morning Nutrition campaign.